PT-140 10mg

PT-140 10mg
£25.00

(NOT FOR HUMAN CONSUMPTION RESEARCH USE ONLY) 

PT-140

is the research name for the synthetic peptide drug bremelanotide, which is FDA-approved under the brand name Vyleesi for treating low sexual desire (hypoactive sexual desire disorder, or HSDD) in premenopausal women. It works through the brain rather than the vascular system, providing a unique mechanism for sexual response. 

 

Mechanism of Action

Unlike traditional erectile dysfunction drugs like Viagra, which work on blood flow, PT-140 activates receptors in the nervous system. 

  • Melanocortin Receptor Agonist: PT-140 primarily activates the melanocortin 4 receptor (MC4R) in the central nervous system (CNS), which is believed to modulate sexual arousal and desire.
  • Neurological Pathway: The exact mechanism is not fully understood, but it is thought to influence mood and sexual desire pathways in the brain. 

 

Approved Medical Use and Administration 

  • Indication: Vyleesi is specifically indicated for premenopausal women with acquired, generalized HSDD that is not caused by other medical or relationship problems. It is not for use in postmenopausal women or men, nor is it for enhancing sexual performance.
  • Administration: It is self-administered as a subcutaneous injection in the abdomen or thigh at least 45 minutes before anticipated sexual activity.
  • Dosage: No more than one dose should be used within 24 hours, and no more than eight doses per month are recommended to minimize side effects like focal skin darkening and increased blood pressure. 

 

Side Effects and Safety

PT-140 is generally well-tolerated, with most side effects being mild to moderate and transient. 

  • Common Side Effects: The most frequently reported adverse reactions are nausea (especially with the first dose), flushing, injection site reactions, and headaches.
  • Cardiovascular Risks: It causes a transient increase in blood pressure and decrease in heart rate after each dose, resolving within 12 hours. It is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease.
  • Other Risks: Potential for darkening of the skin (hyperpigmentation), which may be permanent in some cases, and potential liver injury in rare instances.
  • Drug Interactions: It should not be used with oral naltrexone-containing products as it can decrease the effectiveness of naltrexone.